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Acute cellular rejection (AR) is a major cause of morbidity and mortality after heart transplantation 
(HT). It is characterized by edema, lymphocyte infiltration, and myocyte necrosis.1 Endomyocardial 
biopsy (EMB) is the diagnostic method of choice, as none of the noninvasive methods that have been 
tried have proved to be as efficient.2 However, EMB is invasive and its sensitivity is limited by its 
involving sampling of nonhomogenous tissue.3 and 4 
The electrocardiographic QT interval indicates the total duration of ventricular activity, including 
depolarization and repolarization. Between-lead QT dispersion (QTmax − QTmin) and the analogous 
dispersion (QTcmax − QTcmin) of the “corrected” QT, QTc = {QT(ms)/[1000(ms
−1
) · RR(ms)]
1/2
}, are 
measures of the spatial irregularity of myocardial electrical conduction. Both have been identified as risk 
markers in relation to several cardiopathies, and increased QTc dispersion has been related to increased 
risk of life-threatening ventricular arrhythmias and sudden death.5 and 6 For example, there is growing 
evidence that QT dispersion and QTc dispersion are correlated with the risk of sudden death among 
patients with congestive heart failure,7 left ventricle (LV) hypertrophy due to hypertrophic 
cardiomyopathy,8 ischemic cardiopathy,9 or mitral valve prolapse.10 QT dispersion is also increased in 
patients with arrhythmogenic right ventricular dysplasia.11 
It has been suggested that QT dispersion may be a useful marker or predictor of cardiovascular 
morbidity and mortality due to complex ventricular arrhythmias in patients with rheumatoid arthritis12 or 
Duchenne muscular dystrophy13 or of increased risk of cardiac complications in liver transplant 
candidates.14 The usefulness of QT dispersion analysis in heart transplant patients is still unknown, and 
few studies have been done in this area. It has been suggested that cardiac allograft vasculopathy results 
in ventricular repolarization abnormalities that can be detected by an increase in QTc dispersion15 and 
that QT dispersion might serve as a noninvasive marker of resolution of allograft dysfunction.16 Here we 
report the results of a study of the relationship between QT dispersion and AR status as determined by 
EMB. 
Patients and methods 
Thirty consecutive patients who underwent HT between February 1995 and April 1996 and survived 
longer than 1 month were studied. EMB was performed every 10 days during the first and second months 
after HT, every 15 to 20 days during the third and fourth months, at the end of the fifth and sixth months, 
at various times thereafter, and whenever suspicion of AR arose. EMB specimens were graded in 
accordance with the International Society for Heart and Lung Transplant (ISHLT) classification.17 
Each EMB was accompanied by a standard 12-lead electrocardiogram (ECG) recorded at a paper 
speed of 25 mm/s. A blind observer used callipers to measure QT, the interval between the onset of the 
QRS complex and the end of the T wave. The QT interval for each lead was calculated as the mean over 
three cycles, and the absolute QT dispersion (ΔQT) was calculated by subtracting the shortest of these 
single-lead QTs from the longest. To obtain QTc, each single-lead QT was corrected for the patient’s 
heart rate using Bazett’s formula, QTc = {QT(ms)/[1000(ms−1) · RR(ms)]1/2}, and absolute QTc 
dispersion (ΔQTc) was calculated by subtracting the shortest single-lead QTc from the longest, ΔQTc = 
QTcmax − QTcmin. 
  
Statistical analysis 
Unpaired t tests for comparison of means were performed to detect any connection between QT 
dispersion and AR, which was considered as indicated by an ISHLT EMB grade higher than 2. Analyses 
of variance (ANOVAs) were performed to detect any dependence of QT dispersion at first EMB on donor 
age group (<25 years [11 patients], 25–39 years [13 patients], ≥40 years [6 patients]) or on allograft 
ischemia time (50–100 minutes, 101–170 minutes, 171–240 minutes; 10 patients in each group). 
Results 
A total of 349 ECGs and EMBs were performed on 30 patients. Two ECG/EMB pairs were excluded 
from the analyses due to the EMB material being insufficient for diagnosis. We found no significant 
differences in QT dispersion among EMB grades (Table 1), nor between QTc dispersion and AR status: 
QTc dispersion was 40 ± 17 milliseconds in the AR group (n = 31) and 42 ± 23 milliseconds in the non-
AR group (n = 316). QT dispersion and QTc dispersion decreased with increasing donor age group, but 
the between-group variation was not statistically significant (P > 0.33 and P > 0.27, respectively; see 
Table 2). Nor did ischemia time significantly influence QT dispersion or QTc dispersion (P > 0.83 in both 
cases; see Table 3).  
Table 1. ΔQT, ΔQTc, and Their Source Parameters at Each EMB in Patient Groups Defined by ISHLT EMB Grade 
ISHLT EMB n QTmax (ms) QTmin (ms) RR (ms) ΔQT (ms) QTcmax (ms) QTcmin (ms) ΔQTc (ms) 
         
0 152 357 ± 30 321 ± 27 656 ± 79 35 ± 19 442 ± 33 398 ± 31 43 ± 24 
1A 98 358 ± 26 323 ± 28 671 ± 79 35 ± 19 439 ± 32 395 ± 31 43 ± 24 
1B 21 350 ± 24 322 ± 23 669 ± 64 28 ± 18 429 ± 26 395 ± 25 34 ± 22 
2 45 345 ± 30 316 ± 30 656 ± 79 29 ± 16 427 ± 27 390 ± 26 36 ± 19 
3A 28 345 ± 28 312 ± 25 653 ± 99 32 ± 14 429 ± 27 389 ± 30 40 ± 17 
3B 3 340 ± 20 306 ± 23 643 ± 40 33 ± 11 423 ± 11 382 ± 18 41 ± 14 
Total 349 354 ± 29 320 ± 27 660 ± 79 33 ± 18 437 ± 32 395 ± 30 41 ± 23 
         
 
EMB, endomyocardial biopsy; ISHLT, International Society for Heart and Lung Transplant. 
 
Table 2. QT Dispersion and QTc Dispersion at First Post-HT EMB in Three Groups of Patients 
Defined by Donor Age 
Donor Age (years) n ΔQT (ms) ΔQTc (ms) 
    
<25 11 42 ± 31 51 ± 35 
25–39 13 29 ± 21 34 ± 24 
>=40 6 26 ± 20 31 ± 24 
Total 30 33 ± 25 39 ± 29 
    
 
EMB, endomyocardial biopsy. 
  
Table 3. QT Dispersion and QTc Dispersion at First Post-HT EMB in Three Groups of Patients 
Defined by Ischemia Time 
Ischemia Time (min) n ΔQT (ms) ΔQTc (ms) 
    
50–100 (T1) 10 30 ± 25 35 ± 28 
101–170 (T2) 10 37 ± 33 43 ± 39 
171–240 (T3) 10 34 ± 16 40 ± 19 
Total 30 33 ± 25 39 ± 29 
    
 
EMB, endomyocardial biopsy. 
 
Discussion 
The reproducibility of QT and QTc is controversial. Some authors have reported large variability both 
between successive recordings, with relative errors of 25% to 35%, and between observers (28% to 
33%).18 and 19 Others have found much smaller between-observer variabilities of 5% to 7% and within-
observer variabilities of 4% to 5%.20 The results seem unlikely to have been distorted by measurement 
variability. 
The QT interval is considered to reflect cellular action potential duration. It has been suggested that 
myocardial necrosis and/or edema due to post-HT AR may cause ventricular repolarization 
inhomogeneities that would show up as abnormal QT dispersion. However, in this work, we found no 
correlation between QT dispersion and EMB-defined AR status. Nor were QT dispersion or QTc 
dispersion associated with ischemic time or donor age. These negative results suggest that the limited 
information afforded by QT dispersion concerning the complex electrogenesis of ventricular 
repolarization is insufficient for detection of such inhomogeneities as may be caused by AR at the cellular 
level. It should be borne in mind that there are many other factors apart from rejection that might 
influence ventricular repolarization in HT patients, such as left ventricular mass, systolic and diastolic 
blood pressures, and drug therapy. 
Conclusions 
The results of this study do not support proposals for the use of QTc dispersion for diagnosis of AR in 
HT patients. 
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